SCHEMBL4525155

SCHEMBL4525155

CNC(CNc1nc(-c2ccccc2O)nc2ccccc12)CC(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.59
KMT2A Q03164 12/20 0.59
RXFP1 Q9HBX9 2/20 0.59
MAPT P10636 9/20 0.57
ACP1 P24666 1/20 0.53
HIF1A Q16665 2/20 0.53
NPSR1 Q6W5P4 3/20 0.52
POLB P06746 3/20 0.52
LMNA P02545 2/20 0.52
EGFR P00533 1/20 0.52
PKM P14618 1/20 0.52
PTK2B Q14289 1/20 0.52
GAA P10253 2/20 0.50
ALK Q9UM73 2/20 0.50
NTRK1 P04629 1/20 0.50
PIP4K2A P48426 1/20 0.50
ALDH1A1 P00352 2/20 0.49
HCRTR1 O43613 1/20 0.49
MAPK1 P28482 1/20 0.49
CASP1 P29466 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4525147 1.00 MEN1 (0.59) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL4525152 1.00 MEN1 (0.59) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL4506193 0.85 MEN1 (0.60) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL4506204 0.85 MEN1 (0.60) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL4506199 0.85 MEN1 (0.60) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL4519709 0.83 MEN1 (0.58) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL4519713 0.83 MEN1 (0.58) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL4519715 0.83 MEN1 (0.58) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL3907257 0.82 MEN1 (0.65) MEN1KMT2ARXFP1MAPTACP1
SCHEMBL4501723 0.82 MEN1 (0.65) MEN1KMT2ARXFP1MAPTACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE PKD2, PKD1, AADAT MEN1 4237/4885KMT2A 230/4885RXFP1 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.